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MicroRNAs (miRNAs) are endogenous noncoding RNAs that negatively regulate gene expression by binding the 3′ noncoding
region of the messenger RNA targets inducing their cleavage or blocking the protein translation. They play important roles in
multiple biological and metabolic processes, including developmental timing, signal transduction, and cell maintenance and
differentiation. Their deregulation can predispose to diseases and cancer. miRNA expression has been demonstrated to be
deregulated in many types of human tumors, including thyroid cancers, and could be responsible for tumor initiation and
progression. In this paper we reviewed the available data on miRNA deregulation in different thyroid tumors and describe the
putative role of miRNA in thyroid cancer development.
1. Introduction
MicroRNAs (miRNAs) are endogenous single-stranded non-
coding RNAs of about 22 nucleotides which suppress gene
expression by selectively binding to the complementary 3′
untranslated region (3′-UTR) of messenger RNAs (mRNAs)
through base-pairing. They play important roles in multiple
biological and metabolic processes, such as cell differen-
tiation, proliferation, and survival. Presently, miRNAs are
considered one of the most important regulators of gene
expression at posttranscriptional level, and it has been
estimated that over one third of all human genes could be
targeted by miRNAs [1]. Moreover, miRNAs are strongly
conserved even among different species, strengthening the
hypothesis of their important roles in many essential biolog-
ical processes.
Recent studies have also supported a role of miRNAs
in the initiation and progression of human malignancies.
The analysis of global miRNA expression in cancer patients
showed different patterns of miRNA overexpression or
downregulation in cancer versus normal tissues [2] in
several human tumors, such as colorectal neoplasia [3], B
cell chronic lymphocytic leukaemia [4, 5], B cell lymphoma
[6], lung cancer [7], breast cancer [8], and glioblastoma
[9, 10]. The involvement of miRNAs in human cancer is
probably due to the fact that >50% of miRNA genes are
located at chromosomal fragile sites or common break point
sites or within regions of deletion or amplification that are
generally altered in human tumors [11]. The deregulation of
miRNA expression is suspected to be an important regulator
of tumor development and progression in several human
tissues. The overexpression of specific miRNAs could lead
to the repression of tumor suppressor gene expression,
and conversely the downregulation of specific miRNAs
could result in an increase of oncogene expression; both
these situations induce subsequent malignant effects on
cell proliferation, differentiation, and apoptosis that lead to
tumor growth and progress.
Experimental evidence demonstrated that themajority of
miRNAs present lower expression levels in tumors compared
to normal tissues, independent of the cell type. Global
miRNA expression is higher in normal tissues compared to
their tumoral counterparts or to cancer cell lines. In addition,
poorly differentiated tumors present a lower global level of
miRNA expression compared to more differentiated tumors
[12]. All these data are consistent with the hypothesis that a
higher global miRNA expression is associated with cellular
differentiation. The reduction of global miRNA expression
may reduce cell differentiation that is the hallmark of all
human cancers.
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2. miRNA Transcription, Maturation, and
Mechanisms of Action
miRNAs are transcribed as long, poly-adenylated, and
capped primary transcripts (pri-miRNAs) that are cleaved,
at nuclear level, to ∼60–70 nucleotide hairpin-shaped inter-
mediates (pre-miRNAs) by the nuclear RNase III Drosha
[13]. Following nuclear processing by Drosha, pre-miRNAs
are exported to the cytoplasm by the nuclear transport
receptor exportin-5 [14]. At cytoplasmic level pre-miRNAs
are processed into ∼22 nucleotide miRNA duplexes by the
cytoplasmic RNase III Dicer [15]. These double-stranded
products are unwound by a still unidentified helicase and
incorporated as single-stranded RNAs (guide strand) into
a ribonucleoprotein complex, known as the RNA-induced
silencing complex (RISC) [16]. Which of the two RNA
strands is incorporated in the RISC is determined by the
stability of the base pairs at the 5′ end of the duplex; the
other strand is degraded. The incorporate guide strand leads
the RISC to the complementary sequence in the 3′-UTR
of target mRNA, negatively regulating gene expression at
the posttranscriptional level by targeting the 3′-UTR region
of the mRNAs. Nucleotides 2–8 (referred to as “seed”) of
the mature miRNAs are evolutionary conserved and result
in being crucial in determining target specificity. miRNAs
can downregulate gene expression by two distinct post-
transcriptional mechanisms: mRNA cleavage or translational
repression. The choice of mechanism is determined only by
the identity of the mRNA target and the degree of miRNA-
mRNA complementarity: miRNA will specify induce the
cleavage of mRNA if the target has sufficient complemen-
tarity to the miRNA itself, or it will repress translation if
the mRNA does not have sufficient complementarity [17,
18] (Figure 1). In the first case miRNA may act as small
interfering RNAs (siRNAs) and it cleaves mRNA targets
between the nucleotides pairing to positions 10 and 11 of
the miRNA [19, 20]; after the cleavage of the target the
miRNA remains intact and can guide the recognition and
destruction of other mRNAs [17]. Conversely, the reduced
complementarity between miRNA and its target mRNA gen-
erally creates mismatches and bulges in the central region of
the miRNA-mRNA duplex (at positions 10–12 of the mature
miRNA sequence) that prevent the siRNA-like cleavage of
target mRNA. miRNA-mediated translational repression can
be regulated both at initiation level or at postinitiation level
of the translation process. In the initiation block the RISC
complex inhibits translation by interfering with eIEF4F-cap
recognition and 40S small ribosomal subunit recruit or by
preventing the assembly of the 60S subunit to form the
80S ribosomal complex. In the postinitial block RISC may
inhibit ribosome elongation, inducing ribosome drop-off or
facilitating proteolysis of the nascent polypeptides [21].
Recently, it has been hypothesized a role of miRNAs in
the upregulation of protein translation. A recent study [22]
showed that miR-369-3 linked the AU-rich elements (AREs)
of the TNFαmRNA to upregulate translation, through direct
base pairing between miR-369-3 “seed” region and com-
plementary ARE regions, under cell cycle arrest conditions.
The authors hypothesized that miRNAs may switch between
translation repression or activation based on cell cycle status:
in proliferating cells they repress translation while under cell
cycle arrest they promote translation.
Another study [23] indicated a possible role of miRNAs
in positive activation of translation. The authors found that
miR-10a interacted with the 5′ untranslated region (5′-UTR)
of the mRNAs encoding ribosomal proteins to enhance their
translation. Moreover, miR-10a resulted in being capable
of both translation repression through 3′-UTR binding or
of translation promotion via 5′-UTR binding of different
mRNA targets. These data suggest that the same miRNAmay
exert different effects depending on the site of interaction
with its targets.
3. Identification of miRNA Targets
Identification of miRNA targets and of their specific inter-
action sites is fundamental in the comprehension of miRNA
roles in the regulation of biological processes as well as in the
development of human malignancies.
Some algorithms, such as miRanda (http://www.mic-
rorna.org/microrna/home.do), TargetScan (http://www.tar
getscan.org/), or PicTar (http://pictar.mdc-berlin.de/), have
been developed for the computational prediction of miRNA
targets. All these bioinformatic predictions are primarily
based, and limited, on conserved interactions involving the
miRNA “seed” region and the 3′-UTRs of target mRNAs.
A limitation of these prediction programs is that they are
not able to reveal novel aspects of miRNA target recognition.
False-positive predictions can be eliminated by experimental
validation studies but false-negative predictions remain often
unsolved.
Experimental approaches to miRNA target identification
have mainly focused on analyses of both transcriptome and
proteome expression arrays in cells in which a single miRNA
has been overexpressed or inhibited. Effects on endogenous
target protein levels serve as a good indicator to validate the
miRNA-target interaction. However, this approach suffers
from a limitation: in fact when a miRNA is introduced, by
transfection, in high concentrations into a cell, this may
effect the observed effect on target mRNA and generate false-
positive results, since the level of translation repression is
strongly dependent not only on miRNA and mRNA target
complementarity but also on both the amount of target
mRNA and the amount of available miRNA in the cell
[24].
A direct evidence that a miRNA binds a specific target
mRNA can be obtained by formaldehyde cross-linking of
the miRNA to its targets [22] or by 4-thiouridine-modified
miRNAs [23], both these techniques allow the subsequent
mapping of the exact site of binding using primer extension.
4. miRNA Deregulation in Thyroid Tumors
Thyroid tumors represent a good model for studying multi-
step cancer development in epithelial cells as they comprise
a range of lesions with different degrees of malignancy:
from benign differentiated and noninvasive adenomas to
malignant undifferentiated anaplastic invasive carcinomas.
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Figure 1: Model for miRNA biogenesis and functional mechanisms. miRNA genes are transcribed by RNA polymerase II (pol II) into
primary transcripts (pri-miRNAs) that are cleaved by the Drosha-DGCR8 complex to 60–70 nt pre-miRNAs. Pre-miRNAs are then
transported to the cytoplasm by exportin-5 and there processed by the endonuclease Dicer to generate a double-stranded mature miRNA
of about 21–23 nt. After a strand selection/separation process, the mature miRNA is incorporated into the RISC complex while the other
strand is degraded. RISC complex will recognize and mediate cleavage or repression of specific mRNAs.
The two most common thyroid tumors are papillary thyroid
carcinoma (PTC) and follicular thyroid carcinoma (FTC),
accounting, respectively, for about 80% and 15% of all cases,
both well differentiated and originating from thyroid follicu-
lar cells. PTCs are often multifocal, characterized by classical
papillary architecture, and they usually metastasize to the
regional lymph nodes. FTCs are often unifocal, encapsulated,
and they usually metastasize via the vascular system to
lungs and bones. Both these tumors may progress to poorly
differentiated carcinoma or to completely nondifferentiated
anaplastic carcinoma. Anaplastic thyroid carcinomas (ATCs)
are very rare thyroid cancers (2–5% of all cases), extremely
undifferentiated and highly aggressive. Medullary thyroid
carcinoma (MTC) is a rare thyroid tumor, accounting for
less than 5% of all thyroid cancers, that originates from the
thyroid intrafollicular C cells.
Several independent studies have analyzed miRNA
expression in numerous and different types of thyroid
tumors, evidencing a miRNA deregulation in cancer tissues
compared to their normal counterparts [25–38]; in thyroid
tumors 32% of all known human miRNAs resulted in being
upregulated and 38% to be downregulated with more than a
2-fold change as compared to normal tissues [39]. Moreover,
the miRNA expression profile presents a significant variabil-
ity between different kinds of thyroid cancers, even if they
originate from the same type of thyroid cells [25, 39]. C-cell-
derived MTC has a miRNA expression profile significantly
different from those of thyroid tumors originating from
follicular cells; but also papillary carcinomas, conventional
follicular adenomas and carcinomas, and oncocytic follicular
adenomas and carcinomas, all originating from follicular
cells, show different and specific miRNA expression profiles.
At the moment the exact biological roles of miRNAs in
thyroid carcinogenesis remain to be fully elucidated but
it seems reasonable that the distinctive pattern of miRNA
expression in thyroid tumors compared to normal thyroid
tissue may be useful in diagnosis and/or therapy of thyroid
neoplasia and that different miRNA expression patterns in
different types of thyroid tumors could be useful tools for
their classification.
However, the majority of miRNA profiling studies do
not provide an estimate of miRNA abundance in normal
thyroid tissues and in thyroid tumors. Today, it is recognized
that only the most abundantly expressed miRNAs are able
to occupy a substantial fraction of their mRNA targets,
affecting their translation. The magnitude of translation
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repression is strongly dependent on the number of miRNA-
RISC complexes with respect to the amount of target
mRNA molecules. It is hypothesizable that, among all the
misregulated miRNAs, only those which are abundantly
overexpressed or strongly downregulated are involved in thy-
roid tumorigenesis. The most abundantly expressed miRNAs
in human healthy thyroid gland are listed in Table 1; data
are derived from http://www.mirz.unibas.ch/cloningprofiles/
using the “visualization of miRNA expression profiles” tool.
5. The Role of MicroRNAs in Papillary
Thyroid Carcinoma
Some studies analyzed the miRNA expression profile in PTCs
[26–32] (Table 2).
Comparing global miRNA expression in human PTCs
versus unaffected thyroid tissue He et al. [26] individuated
a set of five miRNAs (miR-146, miR-221, miR-222, miR-21,
and miR-181a) that were significantly overexpressed in PTCs
compared to the adjacent normal tissue. Particularly, three
of them, miR-146, miR-221, and miR-222, showed 11- to
19-fold higher level in tumor tissues. The probe sequence
of miR-146 used in the miRNA array chip was designed
for miR-146a isoform, located on human chromosome 5.
Recently a second isoform, named miR-146b, has been
described on human chromosome 10. These two miRNAs
differ only for two nucleotides in the sequence of their
mature forms. Using primers for premature forms of miR-
146a and miR-146b, no expression of miR-146a was detected
in thyroid tissues by RT-PCR analysis, while a significant
overexpression of miR-146b was found in PTC tumor
samples as confirmed also by Northern blot for mature miR-
146b. Deregulation of miR-146b, miR-221, and miR-222 in
the thyroid may be a crucial component of PTC initiation
and development. The putative target of these miRNAs was
suspected to be KIT, a tyrosine kinase receptor that plays
an important role in cell growth and differentiation, acting
as an oncogene in many cancers [41, 42]. Nevertheless,
neoplastic transformation has been shown to be associated
with either overexpression or downregulation of c-KIT in
different tissues [43–45]. In PTC tissues in which miR-146b,
miR-221, and miR-222 were strongly overexpressed there
was a downregulation of KIT transcript and KIT protein. In
50% of cases the reduced expression of KIT was associated
with germline single-nucleotide changes in both the two
recognition sites of KIT for miR-221 and miR-222 (3′-UTR
region of KIT) and for miR-146b (exon 18 of KIT). In
conclusion, the upregulation of these five specific miRNAs,
and particularly of miR-146b, miR-221, and miR-222, and
the subsequent downregulation of KIT seem to be involved
in PTC pathogenesis, and sequence changes in miRNA target
genes can contribute to their regulation.
c-KIT is frequently expressed in benign thyroid adeno-
mas and goiters, while its expression results in being lowered
in about 60% of FTCs and completely absent in PTCs
and ATCs. Moreover, the absence of c-KIT expression has
been demonstrated also in metastases from primary thyroid
tumors, indicating that the modulation of this tyrosine
Table 1: Most abundantly expressed miRNAs in human healthy
thyroid gland. The table reports the most abundantly expressed
miRNAs in human normal thyroid gland; data are derived from
http://www.mirz.unibas.ch/cloningprofiles/. The tool screened a
total of 768 human miRNAs. Only miRNAs with an abundance
value over 3.0 have been reported in the table.
miRNA Abundance value in thyroid gland
let-7b 56.0
let-7a 52.0
miR-143 47.0
miR-126 39.0
let-7i 32.5
let-7c 29.5
miR-125b 29.0
miR-16 27.0
miR-200c 24.5
miR-26a 23.6666666
let-7f 21.5
miR-23b 16.0
miR-24 14.0
miR-99a 13.0
miR-29a 12.0
miR-30d 12.0
miR-451 12.0
miR-23a 11.0
miR-15a 9.0
miR-27b 9.0
miR-30c 9.0
miR-21 8.0
miR-27a 8.0
miR-30a 8.0
miR-100 8.0
miR-191 8.0
let-7e 7.0
let-7g 6.0
miR-99b 6.0
miR-125a-5p 6.0
miR-145 6.0
miR-195 5.0
let-7d 4.0
miR-25 4.0
miR-206 4.0
miR-10b 3.0
miR-22 3.0
miR-138 3.0
miR-152 3.0
miR-423-3p 3.0
kinase receptor is not dependent on the thyroid microenvi-
ronment but is associated to the transformed malignant cell
phenotype [46]. To date, the biological significance of loss
of c-KIT in thyroid tumors is not elucidated. Surprisingly,
the depletion of c-KIT expression in thyroid tumors in
contrast with the gain of function of other tyrosine kinase
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receptors such as c-RET and c-MET or of oncogenes such
as c-RAS, suggesting that different tyrosine kinase receptor
signaling pathways may exert opposite biological effects in a
given cell type, alternatively controlling mitogenesis or cell
differentiation. It is hypothesizable that, in thyroid tissue,
the c-KIT signaling pathway may control some aspects of the
thyrocyte differentiation rather than cell proliferation.
Pallante et al. [27] analyzed the global miRNA expression
profile in 30 human PTCs versus 10 normal thyroid tissues
using a microarray chip containing 368 human precursor
and mature miRNA oligonucleotide probes, accounting for
245 human and mouse miRNA genes and including all
the three miR-181 human isoforms (miR-181a, miR-181b,
and miR-181c). The analysis revealed an altered miRNA
expression profile that distinguished PTCs from normal
thyroid tissues: five miRNAs (miR-221, miR-222, miR-213,
miR-220, and miR-181b) were overexpressed in the neoplas-
tic tissues. However, a recent work by Chiang et al. [47]
strongly suggested that miR-220 is not a miRNA, and miR-
213 is not recognized as a miRNA in the miRNA database
(http://www.mirbase.org/). The study of Pallante et al. found
that miR-221, miR-222, and miR-181b resulted in being
abundantly expressed in PTCs, while their expression was
only weakly detectable in the healthy thyroid tissues, with the
overexpression of miR-221 reaching up to 70-fold increase.
overexpression of miR-181b has been also confirmed by
quantitative RT-PCR analysis using a couple of primers
specifically designed for precursor of the miR-181b isoform
to exclude a false-positive result for miR-181b, due to
possible cross-hybridization of probes for the miR-181a and
miR-181c isoforms in the microarray chip. The authors also
demonstrated that miR-221 and miR-222 downregulated the
level of c-KIT in PTCs confirming data previously published
[41]. In addition, a human thyroid carcinoma cell line
transfected with a vector over-expressing miR-221 showed
a significant increase of cell growth, and, conversely, the
inhibition of miR-221 function by antisense oligonucleotide
transfection in the same cell line resulted in a significant
reduction of cell growth [27]. The results of these functional
studies, together with the previously reported expression
data, suggest a critical role of miR-221 in thyroid carcinoma
cell growth and, thus, probably in the process of papillary
thyroid carcinogenesis.
A study of Tetzlaff et al. [28] analyzed global miRNA
expression profile by microarray chip (including known
miRNAs from human, mouse, rat, and predicted/candidate
human miRNAs) in a series of PTC formalin-fixed paraffin-
embedded (FFPE) samples versus benign proliferative
multinodular goiters (MNGs). The analysis revealed a set
of 13 upregulated miRNAs and a set of 26 downregulated
miRNAs. Misregulation has been validated by real-time RT-
PCR, in an independent series of tumoral tissues, only
for miR-21, miR-31, miR-221, and miR-222, with miR-
221 and miR-222 showing a strong upregulation in PTCs
compared to independent set of MNGs. Data from this study
confirmed miR-221 and miR-222 to be altered in PTCs, as
previously described in fresh tissue analyses [26, 27] and,
mostly, supported the possibility to use FFPE tumor tissues
to analyze miRNA expression when fresh tissues are not
available or to perform retrospective studies. The author
demonstrated the possibility to extract sufficient miRNA
from FFPE tissues using a miRNA labeling method for
total RNA extracts (All Total Nucleid Acid Isolation SyStem,
Ambion) that bypassed the need for miRNA enrichment
and reduced the amount of starting samples, followed by an
ammonium acetate/ethanol precipitation.
A recent study by Chen et al. [29] analyzed the expression
of a selected set of miRNAs by quantitative RT-PCR in PTCs,
non-PTC lesions (follicular adenoma, follicular carcinoma
hyperplastic nodules), and normal thyroid tissue. They
evidenced an overexpression of miR-146b, miR-221, and
miR-222 in PTCs compared to both non-PTC group and
healthy controls, but with miR-221 and miR-222 presenting
a substantial overlap between different tumor groups. The
authors concluded that the expression analysis of miR-221
and miR-222 cannot be resolving in distinguishing PTCs
from other tumoral lesions. Conversely, miR-146b resulted in
being consistently and specifically overexpressed in classical
PTCs, suggesting this miRNA as a possible diagnostic tool to
identify PTCs from other thyroid tumors. Putative targets of
miR-146b are the nuclear factor-κB (NF-κB), the interleukin-
1 receptor-associated kinase 1 (IRAK1), and the tumor
necrosis factor receptor-associated factor 6 (TRAF6), whose
role in thyroid carcinogenesis has not yet been elucidated.
Mutations of the BRAF gene are implicated in the
pathogenesis of PTC through the constitutive activation
of the MAPK pathway; classical PTCs are often BRAF
mutation positive while follicular PTCs are almost always
BRAF mutation negative [48]. Chen et al. [29] found also
that miR146b overexpression is common both in classical
and follicular variants of PTCs, independently by the BRAF
mutation status, suggesting this overexpression as a late event
in the PTC progression and probably important for the
definition of a complete carcinoma phenotype. This result
has been confirmed also by Sheu et al. [31] who analyzed, in
a series of 221 PTCs, if the BRAF V600E mutational status
was correlated to the miRNA expression profile. They found
no difference in the expression of five miRNAs (miR-146b,
miR-181b, miR-21, miR-221, and miR-222) between BRAF
mutated PTCs and wild-type PTCs. In addition, this study
confirmed the overexpression of miR-146b, miR-221, and
miR-222 as a useful tool to diagnostic PTCs.
More recently, Chou et al. [32] measured the expression
of miR-146b, miR-221, and miR-222 in 100 cases of PTCs
finding that their expression levels were associated with
extra-thyroidal invasion. In particular miR-146b resulted in
being highly expressed in tumors with high risk features and
with the BRAF V600E mutation.
Results from all these studies agreed with the fact that
miR-221 and miR-222 are both overexpressed in PTCs
compared to normal thyroid tissue. Functional analysis on
miR-221 function in human PTC-derived cell lines indicated
a direct role of this miRNA in PTC carcinogenesis. A
vector-induced miR-221 overexpression in these cell lines
resulted in a higher number of cell colonies compared to
negative control transfected cells; conversely, the block of
miR-221 function by antisense oligonucleotide caused a
significant reduction in cell proliferation [27]. A subsequent
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study investigated which pathways or molecular targets were
regulated bymiR-221 andmiR-222 [49]. Some bioinformatic
programs suggested the CDKN1B (p27kip1) gene, an impor-
tant regulator of cell cycle that inhibits the initiation of the S
phase, as the putative target of miR-221 and miR-222. This
study demonstrated that miR-221 and miR-222 negatively
regulate the p27kip1 protein levels in Hela cells and thyroid
carcinoma cells by binding to two specific target sites in the
3′-UTR of the p27kip1 gene. Transfection of TPC-1, thyroid
papillary carcinoma cell line, with vectors for the overexpres-
sion of miR-221 and miR-222 resulted in decreased p27kip1
protein levels. Conversely, inhibition of miR-221 and miR-
222 expression by specific 2′-O-Me-221 and 2′-O-Me-222
antisense oligonucleotides increased the p27kip1 protein lev-
els. In both transfection experiments no significant variation
of p27kip1 mRNA expression was observed. Results from this
study strongly suggested that the overexpression of miR-221
and miR-222 in tumor thyroid cells could be responsible for
the posttranscriptional negative regulation of p27kip1 protein
expression, inducing cells to enter the S phase of cell cycle
and, thus, increasing cell growth.
The RET oncogene mutations occur in about 43% of
PTCs [50], constitutively activating the MAPK signal and
promoting carcinogenesis. These mutations are responsible
for the deregulation of thyroid cell proliferation and dif-
ferentiation and for cell tumoral transformation. Cahill et
al. [40] investigated miRNA expression in two human PTC
cell lines bearing a RET mutation, compared to normal
thyroid cell lines, finding that 21 miRNAs were significantly
overexpressed (miR-34a, miR-96, miR-99a, miR-100, miR-
125b, miR-128b, miR-130b, miR-139, miR-141, miR-142-
3p, miR-146, miR-148, miR-185, miR-200a, miR-200b, miR-
211, miR-213, miR-216 and let-7d) and 14 miRNAs were
downregulated (miR-15a, miR-34c, miR-107, miR-127, miR-
135b, miR-145, miR-149, miR-154, miR-181a, miR-218,
miR-299, miR-302b, miR-302c, miR-323, and miR-370) in
tumor cell lines when compared to normal thyroid. These
differentially expressed miRNAs potentially regulate genes
involved in thyroid functions, and their deregulation could
be implicated in thyroid carcinoma progression.
A functional study of Ricarte-Filho et al. [36] investigated
the involvement of the let-7f miRNA, recently associated
to RAS protein level reduction in lung tumor, in PTC
development. The authors found that, in thyroid RET-
mutated cell lines, the enhanced expression of RET oncogene
reduced the expression of let-7f. The stable transfection
of RET-mutated TPC-1 cell line with vector for the over-
expression of let-7f inhibited the MAPK activation and
reduced cell proliferation. In particular, let-7f increases the
expression of thyroid cell differentiation markers such as the
TITF1 transcription factor, a key factor in normal thyroid
development, and, thus, let-7f is fundamental for the correct
regulation of thyroid cell growth and differentiation and the
reduced expression of let-7f in RET-mutated thyroid cells is
responsible for cell dedifferentiation during PTC malignant
progression. Interestingly, let-7f, together with the miRNA
let-7 family, is one of the most expressed miRNAs in healthy
thyroid gland (Table 1), further suggesting its crucial role in
normal thyroid development and functionality. All these data
suggested let-7f acting as a tumor suppressor and indicated
this miRNA as a potential therapeutic agent in patients with
PTCs bearing a RET mutation.
6. The Role of MicroRNAs in Follicular
Thyroid Carcinoma
Only two studies have analyzed the miRNA expression
alteration in FTCs [25, 33] (Table 2).
In 2006 Weber et al. [33] investigated if miRNAs are
differentially expressed between human follicular thyroid
carcinomas (FTCs) and follicular adenomas (FAs) testing
two high-density miRNA expression arrays on 23 FTCs
versus 20 FA samples and 4 normal thyroid controls.
Four miRNAs (miR-192, miR-197, miR-328, and miR-346)
resulted in being overexpressed in FTCs compared to FAs.
None of these miRNAs have previously been associated
with other thyroid neoplasia and appear to be specific for
FTC phenotype. Two of them, miR-197 and miR-346, have
been validated also by quantitative real-time RT-PCR that
confirmed their significant overexpression in carcinomas
compared to adenomas and healthy tissue. These two
miRNAs may participate in the transformation of follicular
tumors from benign to malignant status, and they and
their target genes may provide novel molecular markers to
differentiate malignant (FTCs) from benign (FAs) follicular
thyroid neoplasia. The effects of these two deregulated miR-
NAs have been functionally investigated using two human
thyroid cancer cell lines, FTC133 and K5, a human papillary
thyroid cancer cell line, NPA87, and a human embryonic
kidney cell line, HEK293T as control. The induction of miR-
197 andmiR-346 overexpression induced cell proliferation in
vitro, whereas their inhibition led to cell growth arrest in both
FTC133 and K5 cell lines, but not in NPA87 cell line, con-
firming that the deregulation of miR-197 and miR-346 is a
marker of FTC phenotype but not of PTC phenotype. In silico
analyses indicated putative targets of miR-197 and miR-346
that have been validated also by in vitro functional analyses.
EFEMP2 (fibulin 4), a protein involved in stabilization and
organization of extracellular matrix structures that exerts
tumor suppressor functions [51, 52], is inhibited by miR-346
overexpression. Activin A receptor type 1 (ACVR1), a potent
inhibitor of cell growth in several human cell types including
thyroid epithelium [53], and tetraspanin 3 (TSPAN3), whose
exact biological role in tumors is still unknown, are both
downexpressed as a consequence of miR-197 overexpression.
Moreover, the authors performed functional studies also on
miR-221 and miR-222 demonstrating that they do not have
a role in FTC tumorigenesis.
More recently, Nikiforov et al. [25] compared miRNA
expression profiles of principal types of thyroid cancers,
finding a distinctive expression pattern associated to fol-
licular thyroid tumors: miR-155, miR-187, miR-221, miR-
222, and miR-224 resulted in being highly overexpressed in
conventional FTCs, while miR-183, miR-187, miR-197, miR-
221, miR-222, and miR-339 were overexpressed in the FTC
oncocytic variants.
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7. The Role of MicroRNAs in Anaplastic
Thyroid Carcinoma
Few studies have analyzed the miRNA expression profiles in
ATCs [34, 35, 37, 38] (Table 2).
Visone et al. [34] analyzed the miRNA expression of
ATCs using a miRNA microarray chip, finding a significant
down-expression of miR-26a, miR-30a-5p, miR-30d, and
miR-125b in ATCs compared to normal thyroid samples.
These data have been further validated by quantitative RT-
PCR, Northern blot analyses, and in situ hybridization.
Induced overexpression of miR-26a and miR-125b in two
human ATC-derived cell lines resulted in cell growth inhi-
bition, suggesting a role of these two miRNAs in negative
cell cycle regulation and that their downregulation could
be involved in thyroid tumorigenesis. No effect on cell
proliferation was observed after induction of miR-30d and
miR-30a-5p overexpression in the same ATC-derived cell
lines. miR-26a influences cell cycle progression by negatively
regulating the expression of EZH2 oncogene, an epigenetic
gene silencer involved in neoplastic development. Recently,
Sander et al. [54] suggested miR-26a acting as a potential
tumor suppressor in MYC-induced tumors, since overex-
pression of miR-26a in murine lymphoma cell lines reduced
cell proliferation by increasing the percentage of cells in G1
phase. miR-125b resulted in being deregulated in several
human tumors, suggesting a role of miR-125b in human car-
cinogenesis [55–57]. An upregulation of miR-125b expres-
sion reduced the proliferation of the CD133-positive glioma
cells and arrested the cell cycle at the G1/S transition level
[58], through the downregulation of CDK6 and CDC25A,
respectively, a cyclin-dependent kinase positively regulating
the transition from the G0/G1 phase to the S phase of the
cell cycle and a positive regulator of G1/S transition by
dephosphorylation and activation of cyclin-CDK complexes.
Both CDK6 and CDC25A have been previously reported to
modulate the G1/S transition in human embryonic stem cells
[59]. Recently, Liang et al. [60] demonstrated that miR-125b
suppresses hepatocarcinoma cell proliferation both in vitro
and in vivo and that this miRNA increases the expression of
p21Cip1/Waf1, arresting cell cycle at the G1 phase.
Another study [38] examined the expression of miRNAs
in ATC-derived cell lines versus PTC-derived cell lines as
well as ATC tissue samples versus PTC tissue samples,
finding that miR-21, miR-146b, miR-221, and miR-222
were overexpressed, while miR-26a, miR-138, miR-219, and
miR-345 were downregulated in ATC cell lines and tissues.
Moreover, since miR-138 resulted in being the unique
miRNA that showed a different expression profile between
ATCs and other follicular cell-derived thyroid tumors, the
authors investigated its putative role in ATC tumorigene-
sis, demonstrating that miR-138 could directly target the
human telomerase reverse transcriptase (hTERT) gene at
posttranscriptional level. hTERT is a catalytic subunit of
telomerase that results in being overexpressed in primary
ATCs compared to PTCs and associated with cell dedif-
ferentiation and increased metastatic potential [61]. The
upregulation of hTERT, subsequent to miR-138 downreg-
ulation, could be responsible for malignant progression of
well-differentiated PTCs toward undifferentiated ATCs. Since
miR-138 downregulation seemed to be strongly associated
with the ATC phenotype, this miRNA could be useful as a
diagnostic tool for ATC recognition and it may contribute to
the development of novel treatment strategy for ATCs.
Takakura et al. [37] reported a group of seven miRNAs
(miR-17-3p, miR-17-5p, miR-18a, miR-19a, miR-19b, miR-
20a, and miR-92-1), compressively named as miR-17-92
cluster, to be overexpressed in ATC cell lines and ATC cancer
lesions compared to adjacent thyroid normal tissues. To
investigate functional role of these deregulated miRNAs in
ATC tumorigenesis, human ATC cell lines have been induced
to silence these miRNAs expression by transfection with spe-
cific miRNA antisenses. Inhibition of miR-17-3p expression
totally suppressed cell growth and induced apoptosis by the
strong activation of caspases 3 and 9. Suppression of miR17-
5p or miR-19a caused a strong reduction of cell prolifer-
ation, not associated with apoptosis or caspase activation.
Moreover, inhibition of miR17-5p, but not of miR-19a, was
also responsible for cell senescence. miR-17-5p and miR-19a
target, respectively, retinoblastoma 1 (RB1) and phosphatase
and tensin homolog (PTEN) genes as confirmed by the fact
that the expression of RB1 and PTEN proteins was increased
in cells transfected with miR-17-5p and miR-19a inhibitors.
Mutations of PTEN gene are associated with Cowden
syndrome characterized by breast and thyroid tumors. PTEN
acts as a tumor suppressor, negatively regulating cell growth
by the repression of the cyclin-dependent kinase inhibitor
p27kip1 expression. A reduced expression of PTEN protein
is associated with thyroid cancer development [62, 63],
and PTEN inactivation is associated with undifferentiated
malignant ATCs, rather than other thyroid tumor types [64].
Therefore, the overexpression of miR-19a (and of its isoform
miR-19b) might be responsible for PTEN posttranscrip-
tional downregulation and subsequent increased cell growth
in ATCs. In addition, downregulation of tumor suppressor
activity of RB1 by overexpression of miR-17-5p could
further contribute to increased tumor cell proliferation.
Selective inhibitors of miR-17-3p, miR-17-5p, and miR-19a
demonstrated to significantly reduce cell growth in ATC-
derived cell lines, and inhibitor of miR-17-3p also induced
cell death. Therefore, these inhibitors could represent valid
therapeutic approaches for the treatment of ATCs.
Very recently, Braun et al. [35] identified two miRNAs,
miR-30 and miR-200, which were significantly downex-
pressed in ATCs compared to PTCs and FTCs. overexpression
of these two miRNAs in mesenchymal ATC-derived cell lines
reduced their invasive and metastatic potential, negatively
regulating the expression of the mesenchymal-epithelial
transition (MET) proteins. Conversely, inhibition of end-
ogenous miR-200 expression was sufficient to induce
the inverse process, the epithelial-mesenchymal transition
(EMT) responsible for tumor cell invasiveness andmetastatic
potential. miR-200 targets the ZEB1 and ZEB2, both repres-
sors of the E-cadherin (CDH1) gene expression. Park et al.
[65] demonstrated, in 60 human cell lines conserved at the
Nation Cancer Institute, a significant association between
miR-200 expression and E-cadherin-vimentin ratio. Induced
overexpression of miR-200 caused the upregulation of
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E-cadherin in tumor cell lines and reduced their motility
and invasiveness. Conversely, the inhibition of miR-200
reduced E-cadherin expression, increased expression of
vimentin, and induced EMT. All these data suggested miR-
200 as a key factor of the epithelial phenotype in cancer cells
that could be used as therapeutic agent to reduce the rates of
invasive and metastatic thyroid carcinomas.
8. The Role of MicroRNAs in Medullary
Thyroid Carcinoma
Only one study [25] has analyzed the miRNA expression in
MTCs compared to other thyroid tumors and normal thyroid
tissue, finding a set of 10 specific miRNAs (miR-9, miR-10a,
miR-124a, miR-127, miR-129, miR-137, miR-154, miR-224,
miR-323, and miR-370) upregulated in this tumor type. No
functional studies have been yet performed.
9. Conclusion and Future Perspectives
miRNAs are powerful key regulators of gene expression
in many fundamental cellular processes such as prolifera-
tion, differentiation, and apoptosis. Deregulation of miRNA
expression was observed in the initiation, development, and
malignant progression of numerous human tumors [2–
10]. miRNA expression profiles resulted in being different
not only between tumors and healthy tissues but also
between different histopathological lesions of the same
tissue, between tumors at different stages of malignancy, and
between primary tumors and metastases. Therefore, miRNA
expression profiles may become useful novel biomarkers for
tumor diagnostic and histological characterization. Recent
findings suggested that miRNA expression profiles could
enable classifying poorly characterized human tumors that
can not be accurately classified only by the classical mRNA
expression patterns [66]. Moreover, since differences in
miRNA expression are, in some cases, associated with the
prognosis, analysis of miRNA expression profiles could help
also in the therapeutic management of patients.
Very recent data supported the possibility to use circulat-
ing miRNAs (plasma, serum, urine, or other body fluids) as
a novel class of biomarkers to diagnose tumors, as expression
patterns of circulating miRNAs are different between normal
tissues and cancers and peculiar miRNA expression profiles
are specifically associated with certain types of tumors [67].
In addition, circulating miRNAs present the advantage to be
stable molecules with a great resistance to RNase activity that
can be easily dosed by noninvasive techniques.
Moreover, since miRNAs regulate cancer cell prolifera-
tion, differentiation, apoptosis, and invasiveness, miRNAs
and their biological targets could be potential targets of
therapeutic genetic strategies in human tumors to interfere
with cancer initiation and progression. miRNAs are pos-
sible targets for a RNA-based therapy both by positively
modulating the expression of specific miRNAs in vivo
using expression vectors [68] and/or by inhibiting miRNA
expression by transfecting specific 2′-O-methyl-modified
antisense RNA (antagomirs) [69].
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